Clinical Trials Logo

Melanosis clinical trials

View clinical trials related to Melanosis.

Filter by:

NCT ID: NCT03565341 Completed - Melasma Clinical Trials

Efficacy and Safety of PiQo4 Device for Treatment of Melasma

Start date: July 2, 2018
Phase: N/A
Study type: Interventional

Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm & 585nm combination treatment. Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits will take place at 1, 3, and 6 months following the last treatment.

NCT ID: NCT03475524 Recruiting - Melasma Clinical Trials

USE THE SYSTEMIC METFORMIN IN MELASMA

Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

Melasma is a chronic and relapsing acquired dyschromia due to an increased epidermal-melanin unit activity that affects sun-exposed areas mainly in women throughout the reproductive years. It is more common in women, accounting for 90% of all cases.The majority of patients are in third and fourth decades of their life. There are several risk factors that influence its appearance including genetic predisposition,exposure to heat and UV radiation, pregnancy, and exogenous hormones (such as oral contraceptives,thyroid hormones, and hormone replacement therapy). Other factors implicated are phototoxic drugs, anticonvulsant medications,and the use of certain cosmetics. Types of melasma are epidermal, dermal and mixed according to location of melanin.

NCT ID: NCT03472235 Not yet recruiting - Melasma Clinical Trials

Microneedle and Trichloroaceticacid in Treatment of Melasma

Start date: April 5, 2018
Phase: N/A
Study type: Interventional

Melasma is an acquired disorder of hyperpigmentation characterised by blotchy, light-to-dark brown macules distributed symmetrically on the sun-exposed parts of the body. Although many factors have been proposed to have a role in pathogenesis, the exact ethology is yet to be understood. The most commonly identifiable risk factors include ultraviolet radiation, genetic predisposition, pregnancy, oral contraceptives, thyroid disease and drugs like antiepileptic. The excessive pigmentation has been attributed to both melanocytosis (increased number of melanocytes) as well as melano genesis (excess production of melanin) as confirmed in a histopathological study on Asian patients.] Furthermore, a vascular component has also been proposed to play a role in the pathogenesis of melisma. Kim et al. have found that lesion melasma skin had greater expression of the vascular endothelial growth factor in keratinocytes compared to nearby nonlesional skin.

NCT ID: NCT03456674 Active, not recruiting - Melasma Clinical Trials

LaseMD System for the Treatment of Melasma

Start date: February 7, 2018
Phase: N/A
Study type: Interventional

This study will evaluate the clinical outcomes associated with use of the LaseMD Laser System for the treatment of melasma.

NCT ID: NCT03415685 Terminated - Melasma Clinical Trials

Lutronic PicoPlus Exploratory Clinical Trial

Start date: October 12, 2017
Phase: N/A
Study type: Interventional

This study will evaluate the use of the Lutronic PicoPlus for treatment of dermatological conditions such as unwanted tattoos and benign pigmented lesions.

NCT ID: NCT03392623 Completed - Melasma Clinical Trials

DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.

Start date: January 1, 2015
Phase: Early Phase 1
Study type: Interventional

BACKGROUND: Malar melasma has a chronic and recurrent character that may be related with epigenetic changes.

NCT ID: NCT03308370 Recruiting - Melasma Clinical Trials

Platelet Rich Plasma in Treatment of Melasma

Start date: November 1, 2017
Phase: Phase 3
Study type: Interventional

Melasma is a common acquired disorder characterized by symmetric, hyperpigmented patches with an irregular outline, occurring most commonly on the face. The therapy for melasma has always been challenging and discouraging. Platelet rich plasma has been used over the last several years as an effective treatment in various surgical and medical fields. In recent years, Platelet rich plasma has also started to be used in the field of cosmetology. This study is designed to evaluate the therapeutic effect of platelet rich plasma in melasma.

NCT ID: NCT03241381 Completed - Clinical trials for Melasma, Periodontitis, Vitamin D Abnormalities, Anaemia

Prevalence of Serum-Vitamin D Abnormalities, Periodontitis and Anaemia in Patients With Melasma

Start date: October 2016
Phase: N/A
Study type: Observational

Melasma is a commonly pigmention characterized by melanotic patches on the face. literature searched revealed that periodontitis and vitamin D deficiency have occurred along with anemia. Actinic associated factors may be indirectly related to vitamin D, melasma contributes to sun exposed area of face.To correlate melasma with clinical evidence of periodontitis and vitamin D serum analysis along side hb %. Patients with facial melasma between 30-70yrs of either gender formed Group A (95). Anaemia and periodontitis were Clinically checked. Additionally serum analysis of vitamin D and hb percentage were analysed. Similar procedure was carried out on controls which had Group B (95) patients with no melasma on face. The study revealed significant correlation between melasma and periodontitis with vitamin D abnormalities (p value<.05), where as insignificant correlation between melasma and Hb%. The correlation between melasma, vitamin d changes and periodontitis may prompt the clinician to check for any such changes in any patient. Melasma in patients with periodontitis and serum vitamin D changes might be a considered as a syndrome.

NCT ID: NCT03153852 Not yet recruiting - Melasma Clinical Trials

Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid

Start date: March 15, 2018
Phase: Phase 4
Study type: Interventional

Melasma is a common acquired disorder of hyperpigmentation characterized by irregular light brown to dark brown patches of hyperpigmentation commonly affecting the face. The trunk and arms are also occasionally involved .

NCT ID: NCT03049059 Completed - Melasma Clinical Trials

A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma

Start date: June 1, 2016
Phase: Phase 2
Study type: Interventional

A Comparative study for Efficacy and Safety Between 4% hydroquinone cream with or without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma